N-type calcium channels located on presynaptic nerve terminals regulate neurotransmitter release, including that from the spinal terminations of primary afferent nociceptors. Accordingly, N-type calcium channel blockers may have clinical utility as analgesic drugs. A selective N-type calcium channel inhibitor, ziconotide (Prialt), is a neuroactive peptide recently marketed as a novel nonopioid treatment for severe chronic pain. To develop a small-molecule N-type calcium channel blocker, the authors developed a 96-well plate high-throughput screening scintillation proximity assay (SPA) for N-type calcium channel blockers using [
INTRODUCTION

C
ALCIUM CHANNELS are believed to be essential for presynaptic neurotransmitter release. 1 Located on presynaptic nerve terminals, N-type calcium channels regulate the influx of calcium in both the central and peripheral nervous systems. 2 Spinal release of primary afferent peptides, such as substance P and calcitonin gene-related peptide, are regulated by N-type calcium channels, 3, 4 suggesting that N-type calcium channel blockers may be potential analgesic drugs. 5 N-type calcium channel blockers have been shown to attenuate both phase 1 and phase 2 of formalin-induced hyperalgesia. 6 Many preclinical studies have demonstrated the efficacy of calcium channel blockers on nerve-injury-induced mechanical allodynia, suggesting that N-type calcium channel inhibitors may have clinical utility in the reduction of neuropathic pain. 7, 8 ω-conotoxin MVIIA (known as SNX-111, Ziconotide, or Prialt™), a selective N-type calcium channel blocker, 9, 10 has been studied in about 2000 human subjects in clinical trials as a novel treatment for severe chronic pain. 11 These studies indicate that N-type calcium channel inhibitors are potential analgesics.
There are several peptidic N-type calcium channel blockers, such as ω-conotoxin GVIA, [12] [13] [14] MVIIA, 15 CVID (also known as AM336), CVIA, CVIB, CVIC, SVIB, TVIA, 16 CNVIIA, 17 PtxIIA, 18 ω-AgaIIIA, 19 MVIIC, [20] [21] [22] and huwentoxin. 23 GVIA, isolated from the venom of Conus geographus, is a 27-aminoacid peptide that is a potent and selective blocker of N-type calcium channels. MVIIA, isolated from the venom of Conus magnus, is another potent and selective N-type calcium channel blocker. MVIIC is an inhibitor for both N-type calcium channels and P/Q-type calcium channels. [20] [21] [22] GVIA and MVIIA are widely used as tools to identify N-type calcium channels. The density of N-type calcium channels in animal tissues or cell membranes has been tested using [
125 I]GVIA [24] [25] [26] or [ 125 I]MVIIA 27, 28 as N-type calcium channelspecific ligands. Usually, a vacuum filtration method is used to separate bound from free ligand. The bound ligand remains on the filter, and the free ligand is washed out with wash buffer.
Currently, there is no non-separation-based binding assay for these N-type calcium channels. Reducing the number of steps and avoiding wash steps are always a consideration for improving the assay especially for robotics platforms. In this study, we developed a scintillation proximity assay (SPA) for N-type calcium channels using [
123 I]GVIA as a N-type calcium channel ligand, eliminating the need for a filtration separation step. Thus, this assay could be carried out in a relatively short time, facilitating its automation for high-throughput screening (HTS).
MATERIALS AND METHODS
Materials
[
125 I]GVIA (specific activity = 2200 Ci/mmol) was obtained from PerkinElmer Life Sciences (Boston, MA). Polyvinyltoluene SPA beads coated with wheat germ agglutinin (WGA-PVT) were obtained from Amersham Bioscience (Piscataway, NJ). The ω-conotoxins GVIA, MVIIA, and MVIIC and ω-agatoxin IVA were purchased from Sigma (St. Louis, MO). Ninety-sixwell Microlite I plates were purchased from Dynex Technologies, Inc. (Chantilly, VA).
Preparation of rat brain membranes
Rat brain membranes were prepared from adult male Sprague-Dawley rat brain tissue according to the procedures described previously. 29 Briefly, rat brain tissue was homogenized in ice-cold 25 mM Tris (pH 7.2), 2 mM EDTA, and 320 mM sucrose and then centrifuged at 1000g for 10 min. The resultant supernatant was then centrifuged at 40,000g for 20 min. The membrane pellet was resuspended in 50 mM HepesTris (pH 7.4) binding buffer and stored at -70 °C until use. The protein concentration in the membrane preparation was determined using the Bradford Reagent (Bio-Rad, Hercules, CA) with bovine serum albumin (BSA) as a standard. 
N-
Scintillation proximity assay
A standard binding assay was performed at room temperature in a 96-well-plate with a total volume of 200 µl. Rat brain membranes were preincubated with WGA-PVT SPA beads for at least 30 min in the binding buffer containing 0.05% BSA. The precoupled SPA beads were incubated with 15 pM [ 125 I]GVIA for 60 min at room temperature. After incubation, the plate was centrifuged and then counted in a PerkinElmer TopCount. Nonspecific binding was determined in the presence of 100 nM unlabelled GVIA. The nonspecific binding was about 15% of total binding. The data were analyzed with GraphPad PRISM.
RESULTS
Effect of incubation time, SPA bead, and membrane protein concentrations on the binding
The association of [ 125 I]GVIA with rat brain membranes at room temperature was rapid and reached near maximal levels by approximately 1 h, with relatively minor incremental increases over the ensuing 19 h (Fig. 1) . Therefore, we chose 1 h as the incubation time in subsequent studies. Binding increased with increasing concentrations of SPA beads or membrane protein ( Fig. 2A, B) . The nonspecific binding for SPA beads and membranes was not significantly changed with increasing SPA beads or membranes within the range tested. A total of 2.5 µg/well membrane protein was used in the following experiment.
Characterization of N-type calcium channels in rat brain membranes
To characterize the N-type calcium channels in rat brain membranes, we examined the binding ability of the N-type A number of calcium channel blockers were tested for their ability to inhibit [ 125 I]GVIA binding. It is well known that GVIA and MVIIA are specific blockers of the N-type calcium channel, whereas ω-agatoxin IVA is a specific P/Q-type calcium channel blocker, and MVIIC blocks both N-type and P/Q-type calcium channels. [30] [31] [32] [33] Inhibition of [ 125 I]GVIA binding to rat brain membranes by these calcium blockers was in the order GVIA > MVIIA > MVIIC >> agatoxin (Fig. 4) . GVIA, MVIIA, and MVIIC binding data were best fit by 1-site models.
SPA for HTS of N-type calcium channels
Library compounds were stored as 1 mM stock solutions containing 30% DMSO. To test the effect of DMSO on binding, varying DMSO concentrations were used. Concentrations of DMSO up to 16% did not significantly affect the assay (data not shown).
To determine well-to-well variance, 48 wells for total binding and 48 wells for nonspecific binding were tested in a 96-well plate. As shown in Figure 5A , the total binding was about 1600 cpm and the nonspecific binding was about 260 cpm, the ratio of total binding to nonspecific binding was about 6, and the calculated Z′ factor 34 was about 0.75. HTS for N-type ]GVIA were added to plates using Caliper's Allegro automation system. Rat brain membranes were added by a MultiDrop-384 (Thermo Electron Corporation, Franklin, MA) to start the reaction. After incubating at room temperature for 60 min, the plates were centrifuged and counted using a PerkinElmer TopCount. The data from 5 plates were analyzed and shown in Figure 5B (Z factor = 0.66). 34 Using this automation method, we screened approximately 150,000 compounds at a rate of more than 10,000 compounds per day. Most (89.3%) of the compounds did not significantly affect [
125 I]GVIA binding (<10% inhibition), whereas 10.5% of the compounds inhibited the binding between 10% and 40%. The hit rate (>40% inhibition of [ 125 I]GVIA binding to rat brain membranes) was about 0.22%, according to the frequency distribution shown in Figure 6 .
DISCUSSION
Because GVIA binds selectively and potently to N-type calcium channels, [
125 I]GVIA has been the ligand of choice for decades. 35 Filtration assays with [ 125 I]GVIA have been used to characterize N-type calcium channels in various tissues and cell lines. There are several disadvantages to using filtration assays for large-scale drug screening. Filtration assays take longer, require large amounts of wash buffer, and generate large quantities of radioactive liquid waste, and very few reliable high-throughput automation systems are able to perform filtration steps. This assay, the 1st to combine [
125 I]GVIA with SPA beads in an automated assay for N-type calcium channel blockers, was simple and rapid.
This assay characterized N-type calcium channels in rat brain membranes and showed that [ 125 I]GVIA selectively bound to high-affinity sites with a K d value of 13 pM and a B max value of 225 fmol/mg. Currently, the most comparable technology with SPA is filtration assay; to date, there are no publications using filtration technology for HTS of N-type calcium channels. Although many N-type calcium channel publications use filtration assays with N-type calcium channel blockers such as GVIA and MVIIA completely and potently inhibited binding. Binding was inhibited by the P/Q-type calcium channel blocker MVIIC but with relatively lower potency. In contrast, agatoxin IVA, another P/Q calcium channel blocker, did not reduce binding to rat brain membranes up to 100 nM. These results, consistent with those of previous reports, 16, 17, 30 support that [ 125 I]GVIA potently blocks N-type calcium channels but not other calcium channels.
The function of calcium channels may also be tested using other methods, such as a calcium flux assay, a fluorescencebased assay, or patch clamp electrophysiological assay, which are all cell-based. Patch clamping is the gold standard for determining calcium channel function, providing high-quality physiologic and functional data at a single-cell and single-channel level. However, electrophysiologic study is limited by its low throughput. [36] [37] [38] Fluorescence-based assays such as the fluorometric imaging plate reader (FLIPR) are widely used for drug discovery. 39 FLIPR assays generally provide robust and homogenous cell population measurements and are relatively easy to set up in a high-throughput manner. The disadvantage of this approach is that the compounds identified may not be selective for the desired target. In the case of the N-type calcium channel, its activity can be modulated by its α2δ subunit, its β subunit, or by G-protein subunits that could provide alternate binding sites for the compound. In addition, the N-type channel pore is similar to other calcium channel pores, such as L-type and P/Q type; therefore, the compounds could inhibit any of these channels nonselectively. Because GVIA specifically binds to N-type calcium channels, the hit compounds identified with a [ 125 I]GVIA binding assay are likely to be selective for the N-type calcium channel. However, as in a filtration assay, a radioactive ligand is used in the present assay. Ligand displacement assays are advantageous for identifying selective hits for this channel. A limitation of binding assays, however, is that they may not detect modulators for this channel acting at other binding sites or via other binding modes. Therefore, the sequential combination of FLIPR and [ 125 I]GVIA binding assays, as primary and secondary screens, respectively, could provide an efficient way to identify and characterize selective N-type calcium channel blockers.
To our knowledge, this is the 1st successfully developed HTS assay for N-type calcium channel blockers using an SPA. The assay was automated with an Allegro system using a 96-well format. More than 150,000 compounds were screened at 10 µM, and about 340 compounds were identified as hits, exhibiting at least 40% inhibition of [ Z factor analysis of scintillation proximity assay (SPA) for N-type calcium channels. Polyvinyltoluene SPA beads coated with wheat germ agglutinin beads (1 mg/well), precoupled with rat brain membranes (2.5 µg/well), were incubated with 15 pM [ 125 I]GVIA for 60 min. Nonspecific binding (NSB) was tested in the presence of 100 nM unlabelled GVIA. The experiment was performed in a 96-well plate, with 48 wells used for total binding and 48 wells used for NSB. The calculated Z′ factor was 0.75 (A). Five initial plates were screened by the system. Control data points including total binding, 70% inhibition, and NSB are indicated to the left of the figure (B). The calculated Z factor was 0.66.
FIG. 6.
Frequency distribution graph of screening data from the Allegro automation system. More than 150,000 compounds at 10 µM were screened, and about 300 compounds were identified as hits, exhibiting at least 40% inhibition of [ 125 I]GVIA binding.
